Plain-English translation of NCT05139706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is building a database of biological samples and medical information from cancer patients treated with immune checkpoint inhibitors—medications that help the body's immune system fight cancer. Researchers want to understand why some patients experience side effects from these treatments and others don't, so they can eventually predict and prevent these complications before they happen.
Immune checkpoint inhibitors have revolutionized cancer care and save lives, but they can trigger unwanted immune reactions that range from mild to serious. Right now, doctors cannot reliably predict who will experience these side effects, and there are no good ways to prevent them. This study aims to identify warning signs in blood and tissue that could help doctors anticipate and manage these complications.
You likely qualify if…
You likely don't qualify if…
You would donate biological samples including blood, plasma, tissue, saliva, or stool, depending on what the study team requests. The study also involves sharing your medical records and clinical information about your cancer treatment and any side effects you've experienced. This is an observational study, meaning researchers are watching and collecting information rather than giving you new medication—you continue your regular cancer treatment as planned.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Canada